BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 27236146)

  • 1.  Hepatorenal syndrome: Current concepts related to diagnosis and management.
    de Mattos ÁZ; de Mattos AA; Méndez-Sánchez N
    Ann Hepatol; 2016; 15(4):474-81. PubMed ID: 27236146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hepatorenal syndrome: diagnosis, treatment and prevention].
    Egerod Israelsen M; Gluud LL; Bendtsen F; Møller S; Krag AA
    Ugeskr Laeger; 2013 May; 175(22):1562-6. PubMed ID: 23721840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.
    Neri S; Pulvirenti D; Malaguarnera M; Cosimo BM; Bertino G; Ignaccolo L; Siringo S; Castellino P
    Dig Dis Sci; 2008 Mar; 53(3):830-5. PubMed ID: 17939047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatorenal syndrome in patients with cirrhosis.
    Moreau R
    J Gastroenterol Hepatol; 2002 Jul; 17(7):739-47. PubMed ID: 12121502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of ascites and hepatorenal syndrome.
    Piano S; Tonon M; Angeli P
    Hepatol Int; 2018 Feb; 12(Suppl 1):122-134. PubMed ID: 28836115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute kidney injury and hepatorenal syndrome in cirrhosis.
    Egerod Israelsen M; Gluud LL; Krag A
    J Gastroenterol Hepatol; 2015 Feb; 30(2):236-43. PubMed ID: 25160511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
    Boyer TD; Sanyal AJ; Wong F; Frederick RT; Lake JR; O'Leary JG; Ganger D; Jamil K; Pappas SC;
    Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of terlipressin in cirrhotic patients with refractory ascites and normal renal function: a multicentric study.
    Fimiani B; Guardia DD; Puoti C; D'Adamo G; Cioffi O; Pagano A; Tagliamonte MR; Izzi A
    Eur J Intern Med; 2011 Dec; 22(6):587-90. PubMed ID: 22075285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico.
    Muñoz LE; Alcalá EG; Cordero P; Martínez MA; Vázquez NY; Galindo S; Mendoza E; Segura JJ
    Ann Hepatol; 2009; 8(3):207-11. PubMed ID: 19841499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: pharmacological treatment of the hepatorenal syndrome in cirrhotic patients.
    Dagher L; Patch D; Marley R; Moore K; Burroughs A
    Aliment Pharmacol Ther; 2000 May; 14(5):515-21. PubMed ID: 10792112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasoconstrictors in hepatorenal syndrome - A critical review.
    Mattos ÂZ; Schacher FC; Mattos AA
    Ann Hepatol; 2019; 18(2):287-290. PubMed ID: 31023616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome.
    Krag A; Borup T; Møller S; Bendtsen F
    Adv Ther; 2008 Nov; 25(11):1105-40. PubMed ID: 19018483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Terlipressin versus other vasoactive drugs for hepatorenal syndrome.
    Israelsen M; Krag A; Allegretti AS; Jovani M; Goldin AH; Winter RW; Gluud LL
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011532. PubMed ID: 28953318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.
    Martín-Llahí M; Pépin MN; Guevara M; Díaz F; Torre A; Monescillo A; Soriano G; Terra C; Fábrega E; Arroyo V; Rodés J; Ginès P;
    Gastroenterology; 2008 May; 134(5):1352-9. PubMed ID: 18471512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COST EFFECTIVENESS OF USING TERLIPRESSIN TO TREAT HEPATORENAL SYNDROME.
    Ferreira LM; Terrabuio DR; Ferreira CM; Mazo DFC; Haddad LBP
    Arq Gastroenterol; 2022; 59(2):268-274. PubMed ID: 35830040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Terlipressin and albumin combination treatment in hepatorenal syndrome.
    Danalioglu A; Cakaloglu Y; Karaca C; Aksoy N; Akyuz F; Ozdil S; Demir K; Besisik F; Boztas G; Mungan Z; Kaymakoglu S; Okten A
    Hepatogastroenterology; 2003 Dec; 50 Suppl 2():ccciii-cccv. PubMed ID: 15244209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring Renal Function and Therapy of Hepatorenal Syndrome Patients with Cirrhosis.
    Juanola A; Solé C; Toapanta D; Ginès P; Solà E
    Clin Liver Dis; 2021 May; 25(2):441-460. PubMed ID: 33838860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatorenal Syndrome: Pathophysiology, Diagnosis, and Treatment.
    Belcher JM
    Med Clin North Am; 2023 Jul; 107(4):781-792. PubMed ID: 37258014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in our understanding of hepatorenal syndrome.
    Wong F
    Nat Rev Gastroenterol Hepatol; 2012 May; 9(7):382-91. PubMed ID: 22614754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival.
    Solé C; Solà E; Huelin P; Carol M; Moreira R; Cereijo U; Mas JM; Graupera I; Pose E; Napoleone L; dePrada G; Juanola A; Fabrellas N; Torres F; Morales-Ruiz M; Farrés J; Jiménez W; Ginès P
    Liver Int; 2019 Jul; 39(7):1246-1255. PubMed ID: 30597709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.